## Michele Bartoletti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2921533/publications.pdf

Version: 2024-02-01

81351 87401 6,433 137 40 76 citations h-index g-index papers 138 138 138 9946 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clinical Microbiology and Infection, 2022, 28, 222-238.	2.8	103
2	AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization. Cancers, 2022, 14, 304.	1.7	3
3	Critically ill patients with COVID-19 show lung fungal dysbiosis with reduced microbial diversity in patients colonized with Candida spp International Journal of Infectious Diseases, 2022, 117, 233-240.	1.5	11
4	Inappropriate use of ivermectin during the COVID-19 pandemic: Primum non nocere!. Clinical Microbiology and Infection, 2022, , .	2.8	7
5	Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups. International Journal of Gynecological Cancer, 2022, 32, 799-803.	1.2	2
6	A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. International Journal of Gynecological Cancer, 2022, 32, 1205-1207.	1.2	5
7	Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. Clinical Microbiology and Infection, 2022, 28, 1290.e1-1290.e4.	2.8	7
8	Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient. Microorganisms, 2022, 10, 778.	1.6	7
9	Dynamic evolution of imipenem/relebactam resistance in a KPC-producing <i>Klebsiella pneumoniae</i> from a single patient during ceftazidime/avibactam-based treatments. Journal of Antimicrobial Chemotherapy, 2022, 77, 1570-1577.	1.3	18
10	Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions. Journal of Fungi (Basel, Switzerland), 2022, 8, 390.	1.5	34
11	Predictive model for bacterial co-infection in patients hospitalized for COVID-19: a multicenter observational cohort study. Infection, 2022, 50, 1243-1253.	2.3	10
12	Risk factors for persistent enterococcal bacteraemia: a multicentre retrospective study. Journal of Global Antimicrobial Resistance, 2022, 29, 386-389.	0.9	3
13	Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients. Critical Care, 2022, 26, .	2.5	41
14	Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. Clinical Infectious Diseases, 2021, 73, e3606-e3614.	2.9	335
15	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. Clinical Nutrition, 2021, 40, 286-294.	2.3	17
16	How do I manage a patient with enterococcal bacteraemia?. Clinical Microbiology and Infection, 2021, 27, 364-371.	2.8	31
17	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. Journal of Hepatology, 2021, 74, 330-339.	1.8	76
18	COVIDâ€19 in solid organ transplant recipients: No difference in survival compared to general population. Transplant Infectious Disease, 2021, 23, e13421.	0.7	50

#	Article	IF	CITATIONS
19	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clinical Microbiology and Infection, 2021, 27, 105-111.	2.8	55
20	COVID-19–Associated Pulmonary Aspergillosis, March–August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	2.0	175
21	Carbapenemase-producing Enterobacteriaceae in transplant patients. Journal of Antimicrobial Chemotherapy, 2021, 76, i27-i39.	1.3	18
22	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS ONE, 2021, 16, e0247275.	1.1	7
23	The role of procalcitonin in reducing antibiotics across the surgical pathway. World Journal of Emergency Surgery, 2021, 16, 15.	2.1	4
24	Prospective Study on Incidence, Risk Factors and Outcome of Recurrent Clostridioides difficile Infections. Journal of Clinical Medicine, 2021, 10, 1127.	1.0	10
25	Re: Treatment duration of enterococcal intravascular catheter-related infections—authors' reply. Clinical Microbiology and Infection, 2021, 27, 493.	2.8	2
26	Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations. Journal of Global Antimicrobial Resistance, 2021, 24, 124-126.	0.9	3
27	Quality of care indicators in the MAnageMent of BlOOdstream infections caused by Enterobacteriaceae (MAMBOO-E study): state of the art and research agenda. International Journal of Antimicrobial Agents, 2021, 57, 106320.	1.1	6
28	Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018. Antibiotics, 2021, 10, 536.	1.5	24
29	Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. International Journal of Gynecological Cancer, 2021, 31, ijgc-2020-002343.	1.2	4
30	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. Hepatology, 2021, 74, 2058-2073.	3.6	45
31	Inhibition of CDK4/6 as Therapeutic Approach for Ovarian Cancer Patients: Current Evidences and Future Perspectives. Cancers, 2021, 13, 3035.	1.7	12
32	Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. Journal of Hepatology, 2021, 75, S101-S117.	1.8	66
33	Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest, 2021, 160, 454-465.	0.4	225
34	Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. BMC Infectious Diseases, 2021, 21, 806.	1.3	11
35	Cell-stiffness and morphological architectural patterns in clinical samples of high grade serous ovarian cancers. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 37, 102452.	1.7	10
36	Histological patterns and intra-tumor heterogeneity as prognostication tools in high grade serous ovarian cancers. Gynecologic Oncology, 2021, 163, 498-505.	0.6	7

3

#	Article	IF	CITATIONS
37	A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol. Journal of Global Antimicrobial Resistance, 2021, 27, 294-298.	0.9	44
38	Self-Therapeutic Cobalt Hydroxide Nanosheets (Co(OH) <sub>2</sub> NS) for Ovarian Cancer Therapy. ACS Omega, 2021, 6, 28611-28619.	1.6	8
39	Blood Hemoglobin Substantially Modulates the Impact of Gender, Morbid Obesity, and Hyperglycemia on COVID-19 Death Risk: A Multicenter Study in Italy and Spain. Frontiers in Endocrinology, 2021, 12, 741248.	1.5	5
40	Advances in the therapy of bacterial bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 158-167.	2.8	33
41	A TGF-Î <sup>2</sup> associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer. Gynecologic Oncology, 2020, 156, 233-242.	0.6	5
42	Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget's disease of the vulva. International Journal of Gynecological Cancer, 2020, 30, 1672-1677.	1.2	17
43	Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer. Pharmacogenomics, 2020, 21, 995-1010.	0.6	2
44	The Role of Obesity in Early and Long-Term Outcomes after Surgical Excision of Lung Oligometastases from Colorectal Cancer. Journal of Clinical Medicine, 2020, 9, 3566.	1.0	1
45	Genetic and Functional Characterization of Toll-Like Receptor Responses in Immunocompetent Patients With CMV Mononucleosis. Frontiers in Cellular and Infection Microbiology, 2020, 10, 386.	1.8	4
46	Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World. Drugs and Aging, 2020, 37, 677-689.	1.3	1
47	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case–Control Study. Open Forum Infectious Diseases, 2020, 7, ofaa233.	0.4	7
48	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. Open Forum Infectious Diseases, 2020, 7, ofaa453.	0.4	7
49	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 1124.	1.6	61
50	Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 3805.	1.8	17
51	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatology, The, 2020, 2, e474-e484.	2.2	772
52	The SENECA study: Prognostic role of serum biomarkers in older patients with metastatic colorectal cancer. Journal of Geriatric Oncology, 2020, 11, 1268-1273.	0.5	6
53	Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study. Future Oncology, 2020, 16, 2059-2073.	1.1	2
54	Biologically driven cut-off definition of lymphocyte ratios in metastatic breast cancer and association with exosomal subpopulations and prognosis. Scientific Reports, 2020, 10, 7010.	1.6	18

#	Article	IF	Citations
55	Use of critical care resources during the first 2 weeks (February 24–March 8, 2020) of the Covid-19 outbreak in Italy. Annals of Intensive Care, 2020, 10, 133.	2.2	31
56	How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre. European Journal of Endocrinology, 2020, 183, 389-397.	1.9	98
57	Microbiological Background: Biofilm, Culturing, and Antibiotics. , 2020, , 17-32.		0
58	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. JHEP Reports, $2019$ , $1$ , $270-277$ .	2.6	12
59	Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. International Journal of Molecular Sciences, 2019, 20, 3390.	1.8	48
60	The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study. Clinical Microbiology and Infection, 2019, 25, 1525-1531.	2.8	34
61	Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1925-1931.	1.3	7
62	Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for A Cost-Effective and Dynamic Biomarker. Cancers, 2019, 11, 1243.	1.7	40
63	Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections. Expert Review of Anti-Infective Therapy, 2019, 17, 819-827.	2.0	22
64	Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers, 2019, 11, 857.	1.7	77
65	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	1.7	67
66	The residual native albumin predicts albumin dysfunction and outcomes in hospitalized cirrhotic patients with acute decompensation or acute-on-chronic liver failure. Digestive and Liver Disease, 2019, 51, e41.	0.4	1
67	PS-102-Circulating native albumin in patients with cirrhosis admitted to hospital for acute decompensation and acute-on-chronic liver failure: Relation to serum albumin levels, albumin function, and patient outcomes. Journal of Hepatology, 2019, 70, e65.	1.8	0
68	SAT-152-Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. Journal of Hepatology, 2019, 70, e698.	1.8	0
69	Clinical experience with dalbavancin for the treatment of deep sternal wound infection. Journal of Global Antimicrobial Resistance, 2019, 18, 195-198.	0.9	11
70	The burden of colonization and infection by carbapenemase-producing Enterobacteriaceae in the neuro-rehabilitation setting: a prospective six-year experience. Infection Control and Hospital Epidemiology, 2019, 40, 368-371.	1.0	3
71	The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 368-377.	2.9	61
72	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	0.6	296

#	Article	IF	Citations
73	Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections. Open Forum Infectious Diseases, 2019, 6, ofz505.	0.4	31
74	Impact on mortality of a bundle for the management of enterococcal bloodstream infection. Open Forum Infectious Diseases, 2019, 6, ofz473.	0.4	16
75	Extended Infusion of $\hat{l}^2$ -Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clinical Infectious Diseases, 2019, 69, 1731-1739.	2.9	29
76	Risk factors for treatment failure in patients receiving $\hat{l}^2$ -lactam/ $\hat{l}^2$ -lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study. International Journal of Antimicrobial Agents, 2019, 53, 574-581.	1.1	3
77	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treatment Reviews, 2019, 72, 7-14.	3.4	25
78	Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA) Journal of Clinical Oncology, 2019, 37, 5564-5564.	0.8	1
79	Long-term toxicity profile of trastuzumab emtansine (T-DM1): A multicenter real-life study Journal of Clinical Oncology, 2019, 37, e12507-e12507.	0.8	2
80	Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA) Journal of Clinical Oncology, 2019, 37, 577-577.	0.8	0
81	Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey. Breast, 2018, 40, 45-52.	0.9	4
82	Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clinical Microbiology and Infection, 2018, 24, 1077-1083.	2.8	47
83	Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: Risk factors and outcome. Digestive and Liver Disease, 2018, 50, 10.	0.4	1
84	Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections. International Journal of Antimicrobial Agents, 2018, 51, 516-521.	1.1	3
85	In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. Journal of Antimicrobial Chemotherapy, 2018, 73, 1525-1529.	1.3	126
86	Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. Gut, 2018, 67, 1892-1899.	6.1	98
87	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	1.1	55
88	A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clinical Microbiology and Infection, 2018, 24, 546.e1-546.e8.	2.8	67
89	2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections. World Journal of Emergency Surgery, 2018, 13, 58.	2.1	154
90	Opportunistic Infections in End Stage Liver Disease. Gastroenterology Insights, 2018, 10, 7621.	0.7	6

#	Article	IF	Citations
91	The role of extended infusion $\hat{l}^2$ -lactams in the treatment of bloodstream infections in patients with liver cirrhosis. Expert Review of Anti-Infective Therapy, 2018, 16, 771-779.	2.0	3
92	Management of immunosuppressive therapy in liver transplant recipients who develop bloodstream infection. Transplant Infectious Disease, 2018, 20, e12930.	0.7	12
93	Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acute decompensation. Journal of Hepatology, 2018, 68, S248.	1.8	0
94	Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: a pilot single-centre study. Journal of Antimicrobial Chemotherapy, 2018, 73, 2856-2859.	1.3	12
95	Use and perception of complementary and alternative medicine among cancer patients: the CAMEO-PRO study. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2029-2047.	1.2	9
96	Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study. Journal of Hepatology, 2018, 68, S44-S45.	1.8	2
97	Multidrug-Resistant Bacterial Infections in Solid Organ Transplant Candidates and Recipients. Infectious Disease Clinics of North America, 2018, 32, 551-580.	1.9	53
98	Procalcitonin-guided antibiotic therapy: an expert consensus. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1223-1229.	1.4	51
99	Perception and opinions of health professionals of an Italian academic hospital about complementary and alternative medicine in oncology Journal of Clinical Oncology, 2018, 36, e18865-e18865.	0.8	0
100	Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to antiâ€ŧubercular treatment. Transplant Infectious Disease, 2017, 19, e12658.	0.7	12
101	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	4.6	367
102	Superficial swab versus deep-tissue biopsy for the microbiological diagnosis of local infection in advanced-stage pressure ulcers of spinal-cord-injured patients: a prospective study. Clinical Microbiology and Infection, 2017, 23, 943-947.	2.8	23
103	Infectious Diseases Team for the Early Management of Severe Sepsis and Septic Shock in the Emergency Department. Clinical Infectious Diseases, 2017, 65, 1253-1259.	2.9	55
104	Characterization of antibody response in neuroinvasive infection caused by Toscana virus. Clinical Microbiology and Infection, 2017, 23, 868-873.	2.8	18
105	An Antimicrobial Stewardship Program Based on Systematic Infectious Disease Consultation in a Rehabilitation Facility. Infection Control and Hospital Epidemiology, 2017, 38, 76-82.	1.0	32
106	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. International Journal of Antimicrobial Agents, 2017, 50, 664-672.	1.1	8
107	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	2.9	43
108	Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 1965-1970.	1.3	17

#	Article	IF	Citations
109	Determinants of adjuvant chemotherapy use in small luminal-like breast cancer Journal of Clinical Oncology, 2017, 35, e12010-e12010.	0.8	O
110	Preliminary results from CAMEO-PRO study: Complementary and alternative medicine in oncologyâ€"Physicians inform oncological patients Journal of Clinical Oncology, 2017, 35, e21632-e21632.	0.8	0
111	Antifungal prophylaxis in liver transplant recipients: one size does not fit all. Transplant Infectious Disease, 2016, 18, 538-544.	0.7	35
112	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Mayo Clinic Proceedings, 2016, 91, 1362-1371.	1.4	89
113	Epidemiology and outcome of candidemia in internal medicine wards: A regional study in Italy. European Journal of Internal Medicine, 2016, 34, 39-44.	1.0	30
114	Reply. Annals of Pharmacotherapy, 2016, 50, 153-153.	0.9	0
115	Bloodstream infections in patients with liver cirrhosis. Virulence, 2016, 7, 309-319.	1.8	67
116	Prevention of infections in nursing homes: antibiotic prophylaxis versus infection control and antimicrobial stewardship measures. Expert Review of Anti-Infective Therapy, 2016, 14, 219-230.	2.0	8
117	Ischaemiaâ€modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver International, 2015, 35, 2425-2432.	1.9	20
118	High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis in Patients Undergoing Liver Transplantation. Transplantation, 2015, 99, 848-854.	0.5	23
119	Meningitis Caused by Toscana Virus Is Associated with Strong Antiviral Response in the CNS and Altered Frequency of Blood Antigen-Presenting Cells. Viruses, 2015, 7, 5831-5843.	1.5	7
120	Risk Factors for Infection With Carbapenem-Resistant Klebsiella pneumoniae. American Journal of Transplantation, $2015,15,1708-1715.$	2.6	99
121	Implementation of a Meningitis Care Bundle in the Emergency Room Reduces Mortality Associated With Acute Bacterial Meningitis. Annals of Pharmacotherapy, 2015, 49, 978-985.	0.9	9
122	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	1.3	434
123	Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case–control–control study. Clinical Microbiology and Infection, 2015, 21, 1106.e1-1106.e8.	2.8	148
124	Infection Complications After Abdominal Organ Transplantation. , 2015, , 33-56.		0
125	Considerations About Antimicrobial Stewardship in Settings with Epidemic Extended-Spectrum $\hat{l}^2$ -Lactamase-Producing or Carbapenem-Resistant Enterobacteriaceae. Infectious Diseases and Therapy, 2015, 4, 65-83.	1.8	40
126	Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clinical Microbiology and Infection, 2015, 21, 242-247.	2.8	63

#	Article	IF	CITATION
127	Klebsiella pneumoniae Bloodstream Infection. Medicine (United States), 2014, 93, 298-309.	0.4	100
128	Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clinical Microbiology and Infection, 2014, 20, 1357-1362.	2.8	182
129	Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. BMC Research Notes, 2014, 7, 32.	0.6	32
130	Role of 18F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1617-1623.	3.3	79
131	Carbapenem-resistant <i>Klebsiella pneumoniae</i> colonization at liver transplantation: A management challenge. Liver Transplantation, 2014, 20, 631-633.	1.3	7
132	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	1.4	75
133	Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. Journal of Hepatology, 2014, 61, 51-58.	1.8	104
134	18F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1190-1196.	3.3	63
135	Incidence and outcome of early <i>Candida</i> peritonitis after liver and pancreas transplantation. Mycoses, 2013, 56, 162-167.	1.8	11
136	Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors. HIV Clinical Trials, 2012, 13, 153-161.	2.0	46
137	Toscana Virus Infections in Northern Italy: Laboratory and Clinical Evaluation. Vector-Borne and Zoonotic Diseases, 2012, 12, 526-529.	0.6	15